Valerie Maduro
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Valerie Maduro.
Nature | 2003
James W. Thomas; Jeffrey W. Touchman; Robert W. Blakesley; Gerard G. Bouffard; Stephen M. Beckstrom-Sternberg; Elliott H. Margulies; Mathieu Blanchette; Adam Siepel; Pamela J. Thomas; Jennifer C. McDowell; Baishali Maskeri; Nancy F. Hansen; M. Schwartz; Ryan Weber; William Kent; Donna Karolchik; T. C. Bruen; R. Bevan; David J. Cutler; Scott Schwartz; Laura Elnitski; Jacquelyn R. Idol; A. B. Prasad; S. Q. Lee-Lin; Valerie Maduro; T. J. Summers; Matthew E. Portnoy; Nicole Dietrich; N. Akhter; K. Ayele
The systematic comparison of genomic sequences from different organisms represents a central focus of contemporary genome analysis. Comparative analyses of vertebrate sequences can identify coding and conserved non-coding regions, including regulatory elements, and provide insight into the forces that have rendered modern-day genomes. As a complement to whole-genome sequencing efforts, we are sequencing and comparing targeted genomic regions in multiple, evolutionarily diverse vertebrates. Here we report the generation and analysis of over 12 megabases (Mb) of sequence from 12 species, all derived from the genomic region orthologous to a segment of about 1.8 Mb on human chromosome 7 containing ten genes, including the gene mutated in cystic fibrosis. These sequences show conservation reflecting both functional constraints and the neutral mutational events that shaped this genomic region. In particular, we identify substantial numbers of conserved non-coding segments beyond those previously identified experimentally, most of which are not detectable by pair-wise sequence comparisons alone. Analysis of transposable element insertions highlights the variation in genome dynamics among these species and confirms the placement of rodents as a sister group to the primates.
American Journal of Human Genetics | 2015
Shannon Marchegiani; Taylor Davis; Federico Tessadori; Gijs van Haaften; Francesco Brancati; Alexander Hoischen; Haigen Huang; Elise Valkanas; Barbara N. Pusey; Denny Schanze; Hanka Venselaar; Anneke T. Vulto-van Silfhout; Lynne A. Wolfe; Cynthia J. Tifft; Patricia M. Zerfas; Giovanna Zambruno; Ariana Kariminejad; Farahnaz Sabbagh-Kermani; Janice Lee; Maria Tsokos; Chyi Chia R. Lee; Victor Evangelista de Faria Ferraz; Eduarda Morgana Da Silva; Cathy A. Stevens; Nathalie Roche; Oliver Bartsch; Peter Farndon; Eva Bermejo-Sánchez; Brian P. Brooks; Valerie Maduro
Ablepharon macrostomia syndrome (AMS) and Barber-Say syndrome (BSS) are rare congenital ectodermal dysplasias characterized by similar clinical features. To establish the genetic basis of AMS and BSS, we performed extensive clinical phenotyping, whole exome and candidate gene sequencing, and functional validations. We identified a recurrent de novo mutation in TWIST2 in seven independent AMS-affected families, as well as another recurrent de novo mutation affecting the same amino acid in ten independent BSS-affected families. Moreover, a genotype-phenotype correlation was observed, because the two syndromes differed based solely upon the nature of the substituting amino acid: a lysine at TWIST2 residue 75 resulted in AMS, whereas a glutamine or alanine yielded BSS. TWIST2 encodes a basic helix-loop-helix transcription factor that regulates the development of mesenchymal tissues. All identified mutations fell in the basic domain of TWIST2 and altered the DNA-binding pattern of Flag-TWIST2 in HeLa cells. Comparison of wild-type and mutant TWIST2 expressed in zebrafish identified abnormal developmental phenotypes and widespread transcriptome changes. Our results suggest that autosomal-dominant TWIST2 mutations cause AMS or BSS by inducing protean effects on the transcription factors DNA binding.
PLOS Genetics | 2017
Yihan Zhang; Haigen Huang; Gexin Zhao; Tadafumi Yokoyama; Hugo Vega; Yan Huang; Raman Sood; Kevin Bishop; Valerie Maduro; John Accardi; Camilo Toro; Cornelius F. Boerkoel; Karen M. Lyons; William A. Gahl; Xiaohong Duan; May Christine V. Malicdan; Shuo Lin
ATP6V1H is a component of a large protein complex with vacuolar ATPase (V-ATPase) activity. We identified two generations of individuals in which short stature and osteoporosis co-segregated with a mutation in ATP6V1H. Since V-ATPases are highly conserved between human and zebrafish, we generated loss-of-function mutants in atp6v1h in zebrafish through CRISPR/Cas9-mediated gene knockout. Homozygous mutant atp6v1h zebrafish exhibited a severe reduction in the number of mature calcified bone cells and a dramatic increase in the expression of mmp9 and mmp13. Heterozygous adults showed curved vertebra that lack calcified centrum structure and reduced bone mass and density. Treatment of mutant embryos with small molecule inhibitors of MMP9 and MMP13 significantly restored bone mass in the atp6v1h mutants. These studies have uncovered a new, ATP6V1H-mediated pathway that regulates bone formation, and defines a new mechanism of disease that leads to bone loss. We propose that MMP9/MMP13 could be therapeutic targets for patients with this rare genetic disease.
PLOS ONE | 2010
Anthony Antonellis; Megan Y. Dennis; Grzegorz M. Burzynski; Jimmy L. Huynh; Valerie Maduro; Chani J. Hodonsky; Mehrdad Khajavi; Kinga Szigeti; Sandeep Mukkamala; Seneca L. Bessling; Nisc Comparative Sequencing Program; William J. Pavan; Andrew S. McCallion; James R. Lupski; Eric D. Green
Background Myelin protein zero (MPZ) is a critical structural component of myelin in the peripheral nervous system. The MPZ gene is regulated, in part, by the transcription factors SOX10 and EGR2. Mutations in MPZ, SOX10, and EGR2 have been implicated in demyelinating peripheral neuropathies, suggesting that components of this transcriptional network are candidates for harboring disease-causing mutations (or otherwise functional variants) that affect MPZ expression. Methodology We utilized a combination of multi-species sequence comparisons, transcription factor-binding site predictions, targeted human DNA re-sequencing, and in vitro and in vivo enhancer assays to study human non-coding MPZ variants. Principal Findings Our efforts revealed a variant within the first intron of MPZ that resides within a previously described SOX10 binding site is associated with decreased enhancer activity, and alters binding of nuclear proteins. Additionally, the genomic segment harboring this variant directs tissue-relevant reporter gene expression in zebrafish. Conclusions This is the first reported MPZ variant within a cis-acting transcriptional regulatory element. While we were unable to implicate this variant in disease onset, our data suggests that similar non-coding sequences should be screened for mutations in patients with neurological disease. Furthermore, our multi-faceted approach for examining the functional significance of non-coding variants can be readily generalized to study other loci important for myelin structure and function.
Orphanet Journal of Rare Diseases | 2016
Valerie Maduro; Barbara N. Pusey; Praveen F. Cherukuri; Paul Atkins; Christèle du Souich; Rosemarie Rupps; Marjolaine Limbos; David Adams; Samarth Bhatt; Patrice Eydoux; Amanda E. Links; Anna Lehman; May Christine V. Malicdan; Christopher E. Mason; Marie Morimoto; James C. Mullikin; Andrew Sear; Clara van Karnebeek; Pawel Stankiewicz; William A. Gahl; Camilo Toro; Cornelius F. Boerkoel
BackgroundMutations of TCF4, which encodes a basic helix-loop-helix transcription factor, cause Pitt-Hopkins syndrome (PTHS) via multiple genetic mechanisms. TCF4 is a complex locus expressing multiple transcripts by alternative splicing and use of multiple promoters. To address the relationship between mutation of these transcripts and phenotype, we report a three-generation family segregating mild intellectual disability with a chromosomal translocation disrupting TCF4.ResultsUsing whole genome sequencing, we detected a complex unbalanced karyotype disrupting TCF4 (46,XY,del(14)(q23.3q23.3)del(18)(q21.2q21.2)del(18)(q21.2q21.2)inv(18)(q21.2q21.2)t(14;18)(q23.3;q21.2)(14pter®14q23.3::18q21.2®18q21.2::18q21.1®18qter;18pter®18q21.2::14q23.3®14qter). Subsequent transcriptome sequencing, qRT-PCR and nCounter analyses revealed that cultured skin fibroblasts and peripheral blood had normal expression of genes along chromosomes 14 or 18 and no marked changes in expression of genes other than TCF4. Affected individuals had 12–33 fold higher mRNA levels of TCF4 than did unaffected controls or individuals with PTHS. Although the derivative chromosome generated a PLEKHG3-TCF4 fusion transcript, the increased levels of TCF4 mRNA arose from transcript variants originating distal to the translocation breakpoint, not from the fusion transcript.ConclusionsAlthough validation in additional patients is required, our findings suggest that the dysmorphic features and severe intellectual disability characteristic of PTHS are partially rescued by overexpression of those short TCF4 transcripts encoding a nuclear localization signal, a transcription activation domain, and the basic helix-loop-helix domain.
American Journal of Medical Genetics Part A | 2016
Elise Valkanas; Katherine E. Schaffer; Christopher Dunham; Valerie Maduro; Christèle du Souich; Rosemarie Rupps; David Adams; Alireza Baradaran-Heravi; Elise Flynn; May Christine V. Malicdan; William A. Gahl; Camilo Toro; Cornelius F. Boerkoel
Failure to thrive arises as a complication of a heterogeneous group of disorders. We describe two female siblings with spastic paraplegia and global developmental delay but also, atypically for the HSPs, poor weight gain classified as failure to thrive. After extensive clinical and biochemical investigations failed to identify the etiology, we used exome sequencing to identify biallelic UNC80 mutations (NM_032504.1:c.[3983‐3_3994delinsA];[2431C>T]. The paternally inherited NM_032504.1:c.3983‐3_3994delinsA is predicted to encode p.Ser1328Argfs*19 and the maternally inherited NM_032504.1:c.2431C>T is predicted to encode p.Arg811*. No UNC80 mRNA was detectable in patient cultured skin fibroblasts, suggesting UNC80 loss of function by nonsense mediated mRNA decay. Further supporting the UNC80 mutations as causative of these siblings’ disorder, biallelic mutations in UNC80 have recently been described among individuals with an overlapping phenotype. This report expands the disease spectrum associated with UNC80 mutations.
American Journal of Medical Genetics Part A | 2015
Aditi Trehan; Jacqueline Brady; Valerie Maduro; William P. Bone; Yan Huang; Gretchen Golas; Megan S. Kane; Paul R. Lee; Audrey Thurm; Andrea Gropman; Scott M. Paul; Gilbert Vezina; Thomas C. Markello; William A. Gahl; Cornelius F. Boerkoel; Cynthia J. Tifft
Intellectual disability (ID) is a heterogeneous condition arising from a variety of environmental and genetic factors. Among these causes are defects in transcriptional regulators. Herein, we report on two brothers in a nonconsanguineous family with novel compound heterozygous, disease‐segregating mutations (NM_015979.3: [3656A > G];[4006C > T], NP_057063.2: [H1219R];[R1336X]) in MED23. This gene encodes a subunit of the Mediator complex that modulates the expression of RNA polymerase II‐dependent genes. These brothers, who had profound ID, spasticity, congenital heart disease, brain abnormalities, and atypical electroencephalography, represent the first case of MED23‐associated ID in a non‐consanguineous family. They also expand upon the clinical features previously reported for mutations in this gene.
Orphanet Journal of Rare Diseases | 2015
Jessica Albert; Nisan Bhattacharyya; Lynne A. Wolfe; William P. Bone; Valerie Maduro; John Accardi; David Adams; Charles E. Schwartz; Joy Norris; Tim Wood; Rachel I. Gafni; Michael T. Collins; Laura L. Tosi; Thomas C. Markello; William A. Gahl; Cornelius F. Boerkoel
BackgroundSnyder-Robinson Syndrome (SRS) is an X-linked intellectual disability disorder also characterized by osteoporosis, scoliosis, and dysmorphic facial features. It is caused by mutations in SMS, a ubiquitously expressed gene encoding the polyamine biosynthetic enzyme spermine synthase. We hypothesized that the tissue specificity of SRS arises from differential sensitivity to spermidine toxicity or spermine deficiency.MethodsWe performed detailed clinical, endocrine, histopathologic, and morphometric studies on two affected brothers with a spermine synthase loss of function mutation (NM_004595.4:c.443A > G, p.Gln148Arg). We also measured spermine and spermidine levels in cultured human bone marrow stromal cells (hBMSCs) and fibroblasts using the Biochrom 30 polyamine protocol and assessed the osteogenic potential of hBMSCs.ResultsIn addition to the known tissue-specific features of SRS, the propositi manifested retinal pigmentary changes, recurrent episodes of hyper- and hypoglycemia, nephrocalcinosis, renal cysts, and frequent respiratory infections. Bone histopathology and morphometry identified a profound depletion of osteoblasts and osteoclasts, absence of a trabecular meshwork, a low bone volume and a thin cortex. Comparison of cultured fibroblasts from affected and unaffected individuals showed relatively small changes in polyamine content, whereas comparison of cultured osteoblasts identified marked differences in spermidine and spermine content. Osteogenic differentiation of the SRS-derived hBMSCs identified a severe deficiency of calcium phosphate mineralization.ConclusionsOur findings support the hypothesis that cell specific alterations in polyamine metabolism contribute to the tissue specificity of SRS features, and that the low bone density arises from a failure of mineralization.
Frontiers of Medicine in China | 2017
Timothy Gall; Elise Valkanas; Christofer Bello; Thomas C. Markello; Christopher Adams; William P. Bone; Alexander J. Brandt; Jennifer M. Brazill; Lynn Carmichael; Mariska Davids; Joie Davis; Zoraida Diaz-Perez; David D. Draper; Jeremy Elson; Elise Flynn; Rena Godfrey; Catherine Groden; Cheng-Kang Hsieh; Roxanne Fischer; Gretchen Golas; Jessica Guzman; Yan Huang; Megan S. Kane; Elizabeth Lee; Chong Li; Amanda E. Links; Valerie Maduro; May Christine V. Malicdan; Fayeza S. Malik; Michele E. Nehrebecky
Traditionally, the use of genomic information for personalized medical decisions relies on prior discovery and validation of genotype–phenotype associations. This approach constrains care for patients presenting with undescribed problems. The National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP) hypothesized that defining disease as maladaptation to an ecological niche allows delineation of a logical framework to diagnose and evaluate such patients. Herein, we present the philosophical bases, methodologies, and processes implemented by the NIH UDP. The NIH UDP incorporated use of the Human Phenotype Ontology, developed a genomic alignment strategy cognizant of parental genotypes, pursued agnostic biochemical analyses, implemented functional validation, and established virtual villages of global experts. This systematic approach provided a foundation for the diagnostic or non-diagnostic answers provided to patients and serves as a paradigm for scalable translational research.
Frontiers of Medicine in China | 2016
Amanda E. Links; David D. Draper; Elizabeth Lee; Jessica Guzman; Zaheer M. Valivullah; Valerie Maduro; Vlad Lebedev; Maxim Didenko; Garrick Tomlin; Michael Brudno; Marta Girdea; Sergiu Dumitriu; Melissa Haendel; Christopher J. Mungall; Damian Smedley; Harry Hochheiser; Andrew M. Arnold; Bert Coessens; Steven Verhoeven; William P. Bone; David Adams; Cornelius F. Boerkoel; William A. Gahl; Murat Sincan
The National Institutes of Health Undiagnosed Diseases Program (NIH UDP) applies translational research systematically to diagnose patients with undiagnosed diseases. The challenge is to implement an information system enabling scalable translational research. The authors hypothesized that similar complex problems are resolvable through process management and the distributed cognition of communities. The team, therefore, built the NIH UDP integrated collaboration system (UDPICS) to form virtual collaborative multidisciplinary research networks or communities. UDPICS supports these communities through integrated process management, ontology-based phenotyping, biospecimen management, cloud-based genomic analysis, and an electronic laboratory notebook. UDPICS provided a mechanism for efficient, transparent, and scalable translational research and thereby addressed many of the complex and diverse research and logistical problems of the NIH UDP. Full definition of the strengths and deficiencies of UDPICS will require formal qualitative and quantitative usability and process improvement measurement.